Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates

Foster, Shonda A; Foley, Kathleen A; Meadows, Eric S; Johnston, Joseph A; Wang, Sara; Pohl, Gerhardt M; Long, Stacey R

doi:10.1186/1472-6874-8-24

BMC Women's Health

Table 3 Multivariate logistic regression results for characteristics associated with raloxifene vs. bisphosphonate use

From: Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates

	Commercial/Medicare		Medicaid
	Odds Ratio¹	95% CI	Odds Ratio¹	95% CI
Age group
45–64	0.881	0.810–0.957	1.509	1.431–1.592
65–74	REFERENCE	---	REFERENCE	---
75 and over	0.686	0.644–0.730	0.813	0.774–0.854
Race
White	---	---	REFERENCE	---
African American	---	---	1.025	0.933–1.126
Hispanic/Latino	---	---	1.070	1.005–1.140
Asian	---	---	1.758	1.665–1.856
Other	---	---	1.299	1.220–1.382
Medicare	0.689	0.630–0.754	---	---
Location
North East	0.672	0.629–0.718	---	---
North Central	0.935	0.898–0.973	---	---
South	REFERENCE	---	---	---
West	0.642	0.609–0.678	---	---
Urban residence	0.819	0.788–0.851	0.667	0.611–0.706
Insurance type
Indemnity	0.986	0.935–1.040	1.128	1.068–1.192
PPO	1.031	0.985–1.079	---	---
Other	REFERENCE	---	REFERENCE	---
Provider specialty
Primary care/Other	REFERENCE	---	REFERENCE	---
Specialist	1.108	1.060–1.158	1.264	1.160–1.377
Health status
CCI	0.941	0.926–0.957	0.962	0.948–0.976
Fracture
Hip	0.449	0.350–0.577	0.659	0.507–0.856
Vertebral	0.664	0.580–0.762	0.744	0.631–0.876
Non-vertebral	0.803	0.758–0.851	0.726	0.674–0.781
BMD test	0.412	0.398–0.426	0.664	0.628–0.703
Mammogram	0.968	0.909–1.031	0.953	0.886–1.026
Confounding conditions
Breast cancer	0.746	0.679–0.819	1.021	0.928–1.123
DVT/PE	0.470	0.245–0.903	0.672	0.438–1.028
Gastric ulcer	2.273	1.181–4.375	0.861	0.585–1.267
Peptic ulcer	2.048	0.964–4.353	1.228	0.942–1.601
Dysphagia	0.974	0.694–1.367	1.200	0.917–1.571
Reflux	1.080	0.897–1.300	1.156	1.005–1.329
Gastritis	0.904	0.666–1.228	1.316	1.156–1.499
Osteoporosis	0.632	0.573–0.697	0.818	0.745–0.898
Medications
Glucocorticoids	0.774	0.737–0.813	0.757	0.713–0.804
Estrogen/HRT	1.325	1.279–1.372	1.501	1.426–1.581

¹Odds ratios that are less than 1.0 indicate that the covariate is associated with a lower likelihood of receiving raloxifene (or is associated with equivalently a higher likelihood of receiving a bisphosphonate). Odds ratios greater than 1.0 indicate that the covariate is associated with a higher likelihood of receiving raloxifene.

Back to article page

ISSN: 1472-6874

Contact us

Submission enquiries: bmcwomenshealth@biomedcentral.com
General enquiries: ORSupport@springernature.com